MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA

Korábbi kezelés

• Previous treatment with triple fixed-dose combination in 12 months prior to inclusion;
• Concomitant uncontrolled disease;
• Participation in other non-interventional observational trials that might, in the investigator's opinion, influence the assessment for the current study, or participation in any observational or clinical trial in the last 30 days prior to inclusion.

Más betegség

• A diagnosis of bronchiectasis, sarcoidosis, interstitial lung disease, or idiopathic pulmonary fibrosis;

Egyéb

• Documented COPD due to α-1 antitrypsin deficiency;
• Pregnancy or lactation period;

• Physician-diagnosed COPD no less than 12 months before BREZTRI treatment start;
• Patients who have not achieved adequate disease control when treated with a combination of ICS and LABA or a combination of LABA and LAMA
• Initiated treatment with BREZTRI ≤12 weeks before inclusion as prescribed according to the label;
• CAT score not more than 1 week before BREZTRI start is available;
• Patients must be able and willing to read, comprehend and follow written instructions, and to comprehend and complete the questionnaires required by the protocol
• Have signed a written Informed Consent Form (ICF).